Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aclarion Equity Warrant Exp 1st Dec 2026 ACONW

Healthcare Medical Devices
Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS), and proprietary biomarkers to optimize clinical treatments. It has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the... see more

Recent & Breaking News (NDAQ:ACONW)

Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MD

GlobeNewswire January 22, 2024

Aclarion Announces Updated Product Release That Expands MRI Scanner Access for Nociscan Solution

GlobeNewswire January 17, 2024

Aclarion and ATEC Execute Strategic Partnership Agreement to Advance Commercialization of Nociscan

GlobeNewswire January 8, 2024

Aclarion Announces Reverse Stock Split

GlobeNewswire January 2, 2024

Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams

GlobeNewswire November 27, 2023

Aclarion Announces Achievement of Goal to Enroll 10 Leading Spine Surgery Key Opinion Leaders (KOLs) to Support Nociscan Adoption

GlobeNewswire November 8, 2023

Aclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MD

GlobeNewswire November 6, 2023

Aclarion Presents at the NIH HEAL Initiative Fall Meeting

GlobeNewswire November 1, 2023

Aclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth facility, to Bring Nociscan Technology to Denver

GlobeNewswire October 25, 2023

Aclarion Announces Nociscan® Cost-Effectiveness Poster Presented at 45th Annual SMDM Meeting

GlobeNewswire October 24, 2023

Aclarion Announces Signing Strategic Partnership Letter of Intent With ATEC to Advance Commercialization of Nociscan

GlobeNewswire October 23, 2023

Aclarion Provides Updated Investor Presentation and Corporate Update

GlobeNewswire October 2, 2023

Aclarion, Inc. Announces Filing of Delayed 10-Q Quarterly Report

GlobeNewswire August 25, 2023

Aclarion Announces New Commercial Engagement with The Imaging Center, Grand Rapids, MI

GlobeNewswire June 14, 2023

Aclarion Announces Statistically Significant Nociscan® Cost-Effectiveness Abstract Presented at ISASS Annual Meeting

GlobeNewswire June 8, 2023

Aclarion Announces New Engagement with The London Clinic and London Spine Clinic

GlobeNewswire May 30, 2023

Aclarion's Key Opinion Leader Program Adds Ninth Surgeon Advisor With Addition of Dean Karahalios, MD

GlobeNewswire May 23, 2023

Aclarion, Inc. Announces Delayed 10-Q Filing

GlobeNewswire May 23, 2023

Aclarion Announces Non-Convertible Debt Financing to Achieve Three Critical Catalysts

GlobeNewswire May 19, 2023

Aclarion Appoints Nicholas Theodore, MD as Principal Investigator for CLARITY Post-Market Trial Evaluating Nociscan in the Diagnosis and Treatment of Chronic Low Back Pain

GlobeNewswire May 2, 2023